M&A / Deals Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities BioSpaceGilead Sciences has inked three deals this year so far totaling $14.77 billion, a marked escalation of the company's usual M A pace.M&A / DealsRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) BioSpace Gilead Sciences has inked three deals this year so far totaling $14.77 billion, a marked escalation of the company’s usual M A pace. M&A / DealsRead full story Post navigation Previous: Medicare Advantage Insurers Will See Higher Payments as CMS Backs Off a Key Payment UpdateNext: With 3 quick buyouts, Gilead leans into its latest transformation Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
